Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

David Smart/Shutterstock.com

The eventual extremity is to make a targeted oncology level for tiny molecules that tin flooded absorption and alteration bystander activity. The remarks travel connected the institution delivering top-line Phase 3 results for Varegacestat successful desmoid tumors. The institution is successful the process of filing a New Drug Application arsenic it sets its sights connected a $1 cardinal marketplace opportunity, targeting the implicit 3,000 patients treated annually.

Immunome besides plans to taxable 3 further INDs this twelvemonth targeting coagulated tumor programs. The propulsion comes arsenic the company’s radioligand therapy, which delivers radiation straight to tumors, receives FDA clearance. It is poised to commencement a objective proceedings soon.

Immunome, Inc. (NASDAQ:IMNM) is simply a clinical-stage biotechnology institution focused connected discovering and processing first-in-class targeted therapies for oncology, chiefly utilizing antibody-drug conjugate (ADC) technology. They usage a proprietary, representation B cell-based find motor to place caller antibodies that dainty cancers.

While we admit the imaginable of IMNM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey connected Google News.